Partial
Partial / Needs Revision
Patient Risk:
Medium
Summary
Several claims are consistent with high-level GLP-1 effects and typical adverse effects, but the provided FDA label excerpt supplied in the prompt only substantiates the boxed warning/Section 5.1 counseling and contraindications for thyroid C-cell tumors. Many other claims (indications, off-label weight loss, pancreatitis risk, dosing/timing of cravings, dopamine/ghrelin mechanisms, specific study details, and specific monitoring) are not supported by the supplied label text and therefore materially limit label alignment.
Category Scores
Accurate Statements
Ozempic (semaglutide) is a medication used to treat type 2 diabetes.
Not supported by the specific FDA label sections excerpted in the prompt (Sections 4 and 5.1 and related counseling only).
Ozempic is a GLP-1 receptor agonist.
Not supported by the specific FDA label sections excerpted in the prompt.
Ozempic can cause side effects such as nausea.
Not supported by the specific FDA label sections excerpted in the prompt.
Ozempic can cause side effects such as vomiting.
Not supported by the specific FDA label sections excerpted in the prompt.
Ozempic can cause side effects such as diarrhea.
Not supported by the specific FDA label sections excerpted in the prompt.
It may take several weeks to notice a difference in cravings after starting Ozempic.
Not supported by the specific FDA label sections excerpted in the prompt.
Unsupported Statements
Ozempic works by mimicking the action of the natural hormone GLP-1.
Mechanism details are not supported by the supplied FDA label excerpt (only thyroid C-cell tumor warning/contraindications and related counseling).
GLP-1 helps regulate blood sugar levels by stimulating insulin release.
Not supported by the supplied FDA label excerpt.
GLP-1 helps regulate blood sugar levels by suppressing glucagon release.
Not supported by the supplied FDA label excerpt.
Ozempic increases insulin production.
Not supported by the supplied FDA label excerpt.
Ozempic decreases glucagon production.
Not supported by the supplied FDA label excerpt.
Ozempic helps to lower blood sugar levels.
Not supported by the supplied FDA label excerpt.
Ozempic helps to improve insulin sensitivity.
Not supported by the supplied FDA label excerpt.
Ozempic can reduce hunger.
Not supported by the supplied FDA label excerpt.
Ozempic can increase feelings of fullness.
Not supported by the supplied FDA label excerpt.
Ozempic slows gastric emptying.
Not supported by the supplied FDA label excerpt.
Ozempic reduces the release of ghrelin, a hormone that stimulates appetite.
Not supported by the supplied FDA label excerpt.
Ozempic decreases the release of dopamine.
Not supported by the supplied FDA label excerpt.
Dopamine is involved in the reward and pleasure centers of the brain.
Not supported by the supplied FDA label excerpt.
Decreased dopamine release from Ozempic can lead to a reduction in cravings for sweets.
Not supported by the supplied FDA label excerpt.
A study in the Journal of Clinical Endocrinology and Metabolism found that patients who took Ozempic for 26 weeks experienced a significant decrease in hunger and food cravings.
Specific study citation/claims are not supported by the supplied FDA label excerpt.
The same study found that hunger/food cravings included a reduction in cravings for sweets.
Specific study citation/claims are not supported by the supplied FDA label excerpt.
Some people who have taken Ozempic can still taste sweets.
Not supported by the supplied FDA label excerpt.
Some people who have taken Ozempic no longer feel the need to indulge in sweets.
Not supported by the supplied FDA label excerpt.
Research has shown that Ozempic can decrease dopamine release.
Not supported by the supplied FDA label excerpt.
Ozempic can reduce cravings for sweets by decreasing dopamine release.
Not supported by the supplied FDA label excerpt.
Ozempic can reduce cravings for sweets by slowing down gastric emptying.
Not supported by the supplied FDA label excerpt.
Ozempic can increase the risk of pancreatitis.
Not supported by the supplied FDA label excerpt (only thyroid C-cell tumors content provided).
The long-term safety of Ozempic is not well established.
Not supported by the supplied FDA label excerpt.
Ozempic is approved for use in people with type 2 diabetes.
Not supported by the supplied FDA label excerpt.
Ozempic is not approved for use in people without diabetes.
Not supported by the supplied FDA label excerpt.
Ozempic may be prescribed off-label for weight loss in people without diabetes.
Not supported by the supplied FDA label excerpt.
Ozempic may interact with certain medications.
Drug interaction information is not included in the supplied FDA label excerpt.
Ozempic can increase the risk of pancreatitis.
Not supported by the supplied FDA label excerpt.
Contradictions
Low
AI Statement
Ozempic can increase the risk of pancreatitis.
Label Reference
No pancreatitis risk statement is present in the supplied FDA label excerpt; therefore this is not verifiably contradicted, but it is unsupported rather than contradicted.
Important Omissions
Boxed warning/Section 5.1 information about thyroid C-cell tumors: rodent findings, unknown human relevance, contraindication in personal/family history of MTC or MEN 2, and patient counseling/symptom examples.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Most claims provided by the AI response are not supported by the supplied FDA label excerpt. While the prompt includes thyroid C-cell tumor warning/contraindications, the AI response content does not clearly reflect those label-specific boxed warning elements, increasing the risk of incomplete safety counseling relative to the provided label basis.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partial / Needs Revision
Primary Issue
Large proportion of mechanism, efficacy/craving claims, study details, pancreatitis risk, and long-term safety statements are unsupported by the supplied FDA label text; thyroid boxed-warning specifics are not addressed in the provided list of claims.
Suggested Improvement
Restrict statements to what is explicitly supported by the supplied FDA label sections (4 and 5.1/17). If providing thyroid tumor boxed-warning information, include the contraindications (MTC personal/family history, MEN 2) and patient symptom counseling as stated in the label excerpt.